Regeneron and Sanofi announce positive results from phase 2b study of dupilumab in patients with atopic dermatitis
Regeneron Pharmaceuticals, Inc., and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic (more…)
Read More
